Walgreens Boots Alliance Analyst Ratings
Morgan Stanley Lowers Price Target on Walgreens Boots Alliance to $9 From $13 Amid Guidance Cut, Keeps Underweight Rating
Nephron Research Cuts Walgreens Boots Alliance's Price Target to $13 From $24, Hold Rating Maintained
Evercore ISI Adjusts Price Target on Walgreens Boots Alliance to $10 From $17
Mizuho Securities Adjusts Price Target on Walgreens Boots Alliance to $19 From $23
Walgreens Boots Alliance Analyst Ratings
Walgreens Boots Alliance Analyst Ratings
Evercore ISI Adjusts Price Target on Walgreens Boots Alliance to $17 From $18, Keeps In Line Rating
Walgreens Boots Alliance Analyst Ratings
Walgreens Boots Alliance: A Sell Rating Amidst Retail Challenges and Generic Pricing Pressures
Hold Rating on Walgreens Boots Alliance Amid Potential Sale of Boots Segment and Financial Implications
TD Cowen Reaffirms Their Buy Rating on Walgreens Boots Alliance (WBA)
TD Cowen Adjusts Price Target on Walgreens Boots Alliance to $35 From $37
HSBC Adjusts Price Target on Walgreens Boots Alliance to $16 From $20
Morgan Stanley Adjusts Price Target on Walgreens Boots Alliance to $16 From $20
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)
RBC Capital Cuts Walgreens Boots Alliance's Price Target to $22 From $26, Sector Perform Rating Kept
Walgreens Boots Alliance Analyst Ratings
Walgreens Boots Alliance Analyst Ratings